Document is current
Any future updates will be listed below
-
Authors
Usmani, Omar S.
Biddiscombe, Martyn F.
Yang, Shuying
Meah, Sally
Oballa, Eunice
Simpson, Juliet K.
Fahy, William A.
Marshall, Richard P.
Lukey, Pauline T.
Maher, Toby M. https://orcid.org/0000-0001-7192-9149
-
Funding
Funding for this research was provided by:
GlaxoSmithKline (COL29296)
-
More Information
Article History
Received: 23 November 2017
Accepted: 31 January 2018
First Online: 6 February 2018
Ethics approval and consent to participate
: The study was approved by the London-Chelsea research ethics committee (11/LO/0372). All subjects provided signed informed consent.
: The institutional consent form was used to cover publication of individual images.
: TMM has received industry-academic funding from GlaxoSmithKline R&D, UCB and Novartis and has received consultancy or speaker’s fees from Apellis, Astra Zeneca, aTyr pharma, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, GlaxoSmithKline R&D, InterMune, ProMetic, Roche, Sanofi-Aventis, and UCB. OSU has received industry-academic funding from Boehringer Ingelheim, Chiesi, Edmond Pharma, GlaxoSmithKline, Mundipharma International, and has received consultancy or speaker fees from Astra Zeneca, Boehringer Ingelheim, Chiesi, Cipla, Edmond Pharma, GlaxoSmithKline, Napp, Novartis, Mundipharma International, Pearl Therapeutics, Roche, Sandoz, Takeda, UCB, Vectura and Zentiva. MFB has received industry-academic funding from Boehringer Ingelheim, Chiesi, and GlaxoSmithKline. PTL, RPM, SY, JKS, EO and WAF are employees and shareholders of GlaxoSmithKline R&D.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
